Delving into the Latest Updates on Ladostigil with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Ladostigil hemitartrate, Ladostigil tartrate, Ladostigil tartrate (USAN)

+ [2]

Target

MAO-A x MAO-B

Mechanism

MAO-A inhibitors(Monoamine oxidase A inhibitors), MAO-B inhibitors(Monoamine oxidase B inhibitors)

Therapeutic Areas

Other Diseases

Active Indication

Cognitive Dysfunction

Inactive Indication

Alzheimer DiseaseAmnesiaDementia+ [1]

Originator Organization

Teva Pharmaceutical Industries Ltd.

Active Organization

Teva Pharmaceutical Industries Ltd.

Inactive Organization

Avraham Pharmaceuticals Ltd.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC20H26N2O8

InChIKeyDZMNQRCPJKPTNC-KBYGAXRISA-N

CAS Registry209394-46-7

View All Structures (2)

The purpose of this study is to determine whether treatment with the investigational drug ladostigil will delay the onset of Alzheimer's disease(AD) in patients with Mild Cognitive Impairment (MCI). MCI is now recognized as a precursor to AD and clinical tools are available to assess cognitive performance at this earlier stage. Ladostigil is currently under investigation for the treatment of AD. In this study, the investigators will be examining ladostigil at a lower dose level. At this dose level, ladostigil has been shown to reduce signs of early memory loss in animals. Thus, in this study the investigators are attempting to determine if earlier invention with a lower dose of ladostigil will significantly reduce initial memory loss and delay the subsequent progression to more serious cognitive dysfunction.

Start Date01 Feb 2012

Sponsor / Collaborator

Avraham Pharmaceuticals Ltd.

NCT01354691

/ CompletedPhase 2

A 6-Month Prospective, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Adaptive-Trial-Design Study to Evaluate the Safety and Efficacy of 80mg b.i.d Ladostigil in Patients With Mild to Moderate Probable Alzheimer's Disease

For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance. There are no known treatments that can either prevent or reverse its progression. Consequently, there still remains a need to evaluate treatments which can better stabilize the symptoms of this disease. These symptoms frequently include decreased functional capacity and negative psychological attributes (e,g, depression, anxiety) in association with the memory and cognition deficits. This current study is being done to assess an investigational compound that has been designed to not only improved the cognitive status of affected patients but to also better manage all symptoms. Hence, the ultimate goal is to provide patients with an improved quality of life by slowing the progression of this neurodegenerative disease

Start Date01 Feb 2011

Sponsor / Collaborator

Avraham Pharmaceuticals Ltd.

EUCTR2010-019858-41-AT

/ Not yet recruitingNot Applicable

A 6-month prospective, multi-center, double-blind, placebo-controlled, randomized, adaptive-trial-design study to evaluate the safety and efficacy of 80mg b.i.d. ladostigil in patients with mild to moderate probable Alzheimer’s Disease with a 6-month open label follow-up period - CR100101/CO15570

Start Date25 Nov 2010

Sponsor / Collaborator

Avraham Pharmaceuticals Ltd.

100 Clinical Results associated with Ladostigil

Login to view more data

100 Translational Medicine associated with Ladostigil

Login to view more data

100 Patents (Medical) associated with Ladostigil

Login to view more data

60

Literatures (Medical) associated with Ladostigil

01 Feb 2021·Iranian journal of basic medical sciencesQ4 · MEDICINE

Alzheimer's disease treatment: The share of herbal medicines.

Q4 · MEDICINE

ReviewOA

Author: Hamidi, Gholamali ; Salami, Mahmoud ; Karimian, Mohammad ; Soheili, Masoud

One of the most frequent forms of dementia in neurological disorders is Alzheimer's disease (AD). It is a chronic neurodegenerative disease characterized by impaired learning and memory. Pathological symptoms as extracellular amyloid-beta (Aβ) plaques and intracellular accumulation of neurofibrillary tangles occur in AD. Due to the aging of the population and increased prevalence of AD, discovery of new therapeutic agents with the highest effectiveness and fewer side effect seems to be necessary. Numerous synthetic medicines such as tacrine, donepezil, galantamine, rivastigmine, memantine, glutathione, ascorbic acid, ubiquinone, ibuprofen, and ladostigil are routinely used for reduction of the symptoms and prevention of disease progression. Nowadays, herbal medicines have attracted popular attention for numerous beneficial effects with little side effects. Lavandula angustifolia, Ginkgo biloba, Melissa officinalis, Crocus sativus, Ginseng, Salvia miltiorrhiza, and Magnolia officinalis have been widely used for relief of symptoms of some neurological disorders. This paper reviews the therapeutic effects of phytomedicines with prominent effects against various factors implicated in the emergence and progression of AD.

26 Oct 2020·Current Pharmaceutical DesignQ4 · MEDICINE

Exploring the Multifunctional Neuroprotective Promise of Rasagiline Derivatives for Multi-Dysfunctional Alzheimer’s Disease

Q4 · MEDICINE

Article

Author: Kabir, Md Tanvir ; Alim, Md Abdul ; Khatkar, Anurag ; Ashraf, Ghulam Md ; Rauf, Abdur ; Al Mamun, Abdullah ; Uddin, Md Sahab ; Rahman, Md Habibur ; Rahman, Md Motiar ; Mathew, Bijo

Alzheimer's disease (AD) is a chronic, age-related, and irreversible brain disorder that typically develops slowly and gets worse over time. The potent auspicious drug candidate for the treatment of AD is supposed to perform the simultaneous modulation of several targets linked to AD. The new therapeutic approach involves drug candidates that are designed to act on multiple targets and have various pharmacological properties. This trend has triggered the development of various multimodal drugs including TV-3326 (i.e. ladostigil) and M-30 (i.e. a new multitarget iron chelator). TV-3326 combines the neurorestorative/neuroprotective effects of the cholinesterase (ChE) inhibitory activity of rivastigmine with rasagiline (a selective monoamine oxidase-B inhibitor and novel antiparkinsonian agent) in a single molecule. M-30, the second derivative of rasagiline, was developed by combining the propargyl moiety of rasagiline into the skeleton of VK-28 (i.e. a novel brain permeable neuroprotective iron chelator). It has been revealed that both the compounds possess anti-AD effects and therefore, the clinical development is directed to the treatment of this type of neurodegenerative diseases (NDs). In this article, we have reviewed the neuroprotective molecular mechanisms and multimodal effects of TV-3326 and M-30.

01 Oct 2020·NeuropharmacologyQ2 · MEDICINE

Effect of ladostigil treatment of aging rats on gene expression in four brain areas associated with regulation of memory

Q2 · MEDICINE

Article

Author: Linial, Michal ; Weinstock, Marta ; Stern, Amos

Episodic and spatial memory decline in aging and are controlled by the hippocampus, perirhinal, frontal and parietal cortices and the connections between them. Ladostigil, a drug with antioxidant and anti-inflammatory activity, was shown to prevent the loss of episodic and spatial memory in aging rats. To better understand the molecular effects of aging and ladostigil on these brain regions we characterized the changes in gene expression using RNA-sequencing technology in rats aged 6 and 22 months. We found that the changes induced by aging and chronic ladostigil treatment were brain region specific. In the hippocampus, frontal and perirhinal cortex, ladostigil decreased the overexpression of genes regulating calcium homeostasis, ion channels and those adversely affecting synaptic function. In the parietal cortex, ladostigil increased the expression of several genes that provide neurotrophic support, while reducing that of pro-apoptotic genes and those encoding pro-inflammatory cytokines and their receptors. Ladostigil also decreased the expression of axonal growth inhibitors and those impairing mitochondrial function. Together, these actions could explain the protection by ladostigil against age-related memory decline.

100 Deals associated with Ladostigil

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03239	-	-	DB16213

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 2	RS	Avraham Pharmaceuticals Ltd.	01 Feb 2011
Alzheimer Disease	Phase 2	HR	Avraham Pharmaceuticals Ltd.	01 Feb 2011
Alzheimer Disease	Phase 2	DE	Avraham Pharmaceuticals Ltd.	01 Feb 2011
Alzheimer Disease	Phase 2	ES	Avraham Pharmaceuticals Ltd.	01 Feb 2011
Alzheimer Disease	Phase 2	AT	Avraham Pharmaceuticals Ltd.	01 Feb 2011
Amnesia	Phase 2	DE	Avraham Pharmaceuticals Ltd.	01 Feb 2011
Amnesia	Phase 2	AT	Avraham Pharmaceuticals Ltd.	01 Feb 2011
Amnesia	Phase 2	RS	Avraham Pharmaceuticals Ltd.	01 Feb 2011
Amnesia	Phase 2	ES	Avraham Pharmaceuticals Ltd.	01 Feb 2011
Cognitive Dysfunction	Phase 2	-	Teva Pharmaceutical Industries Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01354691 (CTgov)	Phase 2	Alzheimer Disease \| Cognitive Dysfunction \| Amnesia	200	ladostigil hemitartrate (Ladostigil Hemitartrate)	igsqqfnfvt(ygwstrtpxf) = niyzbihowc aavnygygep (llihccjbyb, fwzxdewmgl - icqpfotrjr) View more	-	30 Jul 2020
				ladostigil hemitartrate (Placebo)	igsqqfnfvt(ygwstrtpxf) = cogeipbtnb aavnygygep (llihccjbyb, szjbgjhplw - wvyxbdfmfy) View more
NCT01429623 (CTgov)	Phase 2	Mild cognitive disorder \| Dementia	210	ladostigil hemitartrate (Ladostigil Hemitartrate)	dvmjkmqdkx(pyclzxudef) = hjuqlgmwcs reiqffjrak (nbrvccqgul, pecanvtwux - lgzwlvkjns) View more	-	15 Jun 2017
				Placebo (Placebo Control)	dvmjkmqdkx(pyclzxudef) = cseuelbyll reiqffjrak (nbrvccqgul, obnlezkqyf - abplbmvlaq) View more